Built on a site of 8 000 m2, our unit of Oued Smar (Algiers,Algeria) manufactures today some 35 million units per year, through 9 lines of production, that is two (2) lines for the liquid forms (small and large volumes), a line of creams and gels, two lines of suppositories and four lines of dry forms (bags, powder, pills and tablets). Our production range includes nearly hundred of generic covering the main therapeutic classes.

The pharmaceutical laboratory Biopharm contributes, since the launch of its manufacture in 2005, to the creation of new jobs with high added value, the development of innovative generic and to the reduction of the external dependency of our country, in an industrial complex and demanding sector.

From the outset, our option was that of a sustainable commitment for the quality and, in consequence, that of the investment in the human resources and the permanent training of our teams. In the scrupulous respect of Good Manufacturing Pharmaceuticals Practices (GMP), the quality control of each drug is exercised in a continuous way, in all phases of its manufacture and applies to the whole of its components. Our department of quality assurance, supported itself on a control laboratory  provided with the most modern equipment, supervises all the operations of production and this, up to the final delivery of our products.

At the heart of the activities of our factory, there is a research and development laboratory whose performance allows us to formulate each year nearly a half of new generic products and to proceed with the launch of their manufacture.

At Biopharm, we export since 2011 a fortnight of our products to the African market (Tunisia, Libya, Mauritania, Mali, and Niger). The approval in 2015 of our production unit of Oued Smar by the French MSNA (National Agency for the safety of the drug and health products) opens us, in the long term, opportunities to export to the European market.